Copper Depletion in Tumors Boosts Immunotherapy.

Abstract

Copper depletion is being billed as a viable approach for cancer treatment. Vittorio and co-workers successfully demonstrated that Cuprior, an FDA-approved drug that binds with copper, effectively enhances anti-GD2 immunotherapy and improves the responses for neuroblastoma patients. These findings highlight the important role of copper chelation in modulating the tumor microenvironment. This study presented a novel approach to potentiate immunotherapies for neuroblastoma patients, warranting further investigations into copper depletion as a potential adjuvant therapy for other tumors.